OncoC4 Announces FDA Clearance of IND Application for Novel SIGLEC 10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors
April 23, 2024 08:00 ET
|
OncoC4, Inc.
ONC-841 is a potential first-in-class SIGLEC 10 antibody designed to block an innate and potentially adaptive immune checkpoint and prevent cancer evasion of immune cellsAnti-tumor T cells, NK cells...
OncoC4 Expands Scientific Advisory Board with Appointment of Heather A. Wakelee, MD, FASCO
April 02, 2024 08:00 ET
|
OncoC4, Inc.
Dr. Wakelee is a world-renowned expert in the research and treatment of lung cancerOncoC4’s SAB now includes 6 distinguished scientists, industry experts, and key opinion leaders in oncology and...
OncoC4 Announces First Patient with Advanced Prostate Cancer Dosed in Phase 1/2 Trial of BioNTech-partnered BNT316/ONC-392 Program
February 22, 2024 08:00 ET
|
OncoC4, Inc.
The Phase 1/2 trial will assess the efficacy and safety of BNT316/ONC-392 in combination with the radioligand therapy lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with metastatic...
OncoC4 to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024 08:00 ET
|
OncoC4, Inc.
ROCKVILLE, Md., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer, today announced its participation in the 42nd...
OncoC4 Strengthens Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer
September 28, 2023 08:00 ET
|
OncoC4, Inc.
ROCKVILLE, Md., Sept. 28, 2023 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, today announced the appointment of Abid Ansari as Chief...
UPDATE - OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
December 30, 2022 10:43 ET
|
OncoC4, Inc.
ROCKVILLE, Md., Dec. 30, 2022 (GLOBE NEWSWIRE) -- OncoC4, Inc., a clinical-stage biopharma company developing novel immunotherapies for cancer, today announced that the first patient has been dosed...
OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
December 30, 2022 08:27 ET
|
OncoC4, Inc.
The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous clinical trial ONC-392 is the first known acid...
OncoC4 to Present Positive Data from Ongoing Phase 1/2 PRESERVE-001 Trial of ONC-392 in Combination with pembrolizumab at SITC 2022
November 07, 2022 08:00 ET
|
OncoC4, Inc.
30% ORR and 90% DCR in evaluable patients were achieved in the dose escalation portion of the study in metastatic cancer patientsInitial results from dose-expansion show 5 partial responses (PR) and 1...
OncoC4 Announces Fast Track Designation Granted by the U.S. FDA for ONC-392 Monotherapy in PD(L)1-Resistant NSCLC
April 26, 2022 08:00 ET
|
OncoC4, Inc.
ROCKVILLE, Md., April 26, 2022 (GLOBE NEWSWIRE) -- OncoC4, Inc., a clinical stage biopharma company developing novel immunotherapies for cancer, announced today that the U.S. Food and Drug...
OncoC4, Inc. Reports Phase Ia Data on Safety and Clinical Activities of ONC-392 (Nextgen Anti-CTLA-4) Monotherapy for Stage IV Solid Tumors
November 09, 2021 08:00 ET
|
OncoC4, Inc.
Data Suggest that ONC-392 Monotherapy has Promising Anti-tumor Activity in Stage IV Cancer Patients Who Have Failed Multiple Lines of Prior Therapy Company Plans to advance into Phase II/III studies ...